First-in-human studies in sight, SQZ's cell therapy tech wins over a diverse group of investors in $72M round
Having steadily built out the preclinical data to cement its cell therapy platform and sorted out the technicalities, SQZ Biotech has raised $72 million to make its first drive to the clinic.
The Series C marks the biggest round by far for Boston-based SQZ, which launched out of the labs of MIT’s Robert Langer and Klavs Jensen in 2014 with $1 million in seed funding.
CEO Armon Sharei tells me the oversubscribed round — bringing in new investors including Illumina Ventures, Invus, Viva Ventures Biotech Group, Everblue and Orient Life — is a reflection of the company’s progress in validating its approach to engineering cells for therapeutic purposes. The team is now lining up an IND in HPV+ tumor indications for the end of the year, with the first clinical results expected by next year. Trials in autoimmune diseases will follow.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.